Electrodo de Anillo

Información básica

• Disponible en:
• English
• Español

The EarlyTect Colon Cancer Test is a breakthrough product in the field of colorectal cancer screening. This test has been rigorously tested and approved by the Korea Ministry of Food and Drug Safety, following clinical trials conducted at renowned medical centers such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center.

Unlike traditional screening methods, the EarlyTect Colon Cancer Test utilizes a qualitative real-time PCR technology to detect methylated Syndecan-2 (SDC2) in stool DNA. This biomarker has been clinically proven to be associated with precancerous lesions of colorectal cancer. Through these advanced testing methods, the EarlyTect Colon Cancer Test can accurately diagnose colorectal cancer with an impressive 90% sensitivity and specificity.

It is important to note that while the EarlyTect Colon Cancer Test is highly reliable in detecting precancerous lesions of colorectal cancer, it is not intended to confirm the presence of colorectal cancer itself. In the event of a positive result, further evaluation is required to determine if colorectal cancer or precancerous lesions of colorectal cancer exist.

The product conforms to the following standards:
- Cancer Type: Colorectal Cancer
- Target Subjects: Asymptomatic individuals seeking colorectal cancer screening
- Biomarker: SDC2 methylation

For pricing and transaction details, we offer flexibility and negotiability. Please feel free to request a quote to initiate the transaction.